Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement
23. Dezember 2022 16:01 ET
|
Metacrine, Inc.
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger...
Metacrine Reports Third-Quarter 2022 Results
14. November 2022 16:38 ET
|
Metacrine, Inc.
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal...
Metacrine Reports Second-Quarter 2022 Results
09. August 2022 16:05 ET
|
Metacrine, Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...
Metacrine Reports First-Quarter 2022 Results
12. Mai 2022 16:05 ET
|
Metacrine, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases,...
Metacrine Reports Fourth-Quarter 2021 Results
30. März 2022 16:05 ET
|
Metacrine, Inc.
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...
Metacrine Announces Executive Leadership Changes
24. Februar 2022 16:05 ET
|
Metacrine, Inc.
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...
Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan
11. Februar 2022 08:05 ET
|
Metacrine, Inc.
U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitisSufficient capital to complete Phase 2 IBD trial SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc....
Metacrine Announces Resignation of Chief Medical Officer
27. Dezember 2021 08:00 ET
|
Metacrine, Inc.
SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and...
Metacrine Reports Third-Quarter 2021 Results
11. November 2021 08:00 ET
|
Metacrine, Inc.
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and...
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
02. November 2021 08:00 ET
|
Metacrine, Inc.
- Validates therapeutic benefit of combination approaches for a large segment of NASH patients- Demonstrates additive efficacy results and favorable tolerability profile SAN DIEGO, Nov. 02, 2021...